Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: XPO1
Name: exportin 1
Location: 02p15
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT02649790 Study of the Safety Tolerability and Efficacy of KPT-8602 in Participants With RelapsedRefractory Cancer Indications View
NCT04764942 Selinexor Pomalidomide and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma The SCOPE Trial View
NCT02137356 Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer View
NCT02323880 Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas View
NCT02667873 A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors View
NCT02757586 Treatment of Chronic Lymphocytic Leukemia View
NCT02815137 Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma View
NCT03095612 Phase 12 Trial of Selinexor KPT-330 With Docetaxel for Non-small Cell Lung Cancer NSCLC View
NCT06552559 Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma View
NCT05170789 Elotuzumab Selinexor and Dexamethasone for Relapsed Refractory Multiple Myeloma View
NCT05952687 Trial of Idasanutlin and Selinexor Therapy for Children With ProgressiveRelapsed ATRT or Extra-CNS Malignant Rhabdoid Tumors View
NCT05833893 Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NKT-cell Lymphoma View
NCT04856189 Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma View
NCT05985161 A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors View
NCT06225310 A Trial of Selinexor Ruxolitinib and Methylprednisolone View